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t-cell responses following natural 
Influenza Infection or Vaccination in 
Solid organ transplant Recipients
Arnaud G. L’Huillier1,2, Victor H. ferreira2, Cedric Hirzel2,3, Srinivas nellimarla4, Terrance Ku2, 
Yoichiro natori5,6, Atul Humar2 ✉ & Deepali Kumar2 ✉
Little is known about cell-mediated immune responses to natural influenza infection in solid organ 
transplant (SOT) patients. The aim of our study was to evaluate the CD4+ and CD8+ responses to 
influenza A and B infection in a cohort of SOT patients. We collected peripheral blood mononuclear 
cells at influenza diagnosis and four weeks later from 31 SOT patients during the 2017–2018 influenza 
season. Infection-elicited influenza-specific CD4+ and CD8+ T-cell responses were measured using flow 
cytometry and intracellular cytokine staining and compared to responses following influenza vaccine 
in SOT patients. Natural infection was associated with a significant increase in CD4+ t-cell responses. 
For example, polyfunctional cells increased from 21 to 782 and from 193 to 1436 cells per 106 CD4+ 
T-cells among influenza A/H3N2 and B-infected patients (p = 0.006 and 0.004 respectively). Moreover, 
infection-elicited CD4+ responses were superior than vaccine-elicited responses for influenza A/H1N1 
(931 vs 1; p = 0.026), A/H3N2 (647 vs 1; p = 0.041) and B (619 vs 1; p = 0.004). Natural influenza infection 
triggers a significant increase in CD4+ T-cell responses in SOT patients. Infection elicits significantly 
stronger CD4+ responses compared to the influenza vaccine and thereby likely elicits better protection 
against reinfection.
Solid organ transplant (SOT) recipients are at increased risk for morbidity and mortality following influenza virus 
infection because of lifelong immunosuppression required to avoid graft rejection1,2. The main preventive strategy 
against influenza is yearly immunization with the inactivated influenza vaccine, which is recommended for all 
SOT recipients3,4. Nevertheless, transplant recipients may develop influenza despite adequate immunization1, 
which in part may be related to inadequate vaccine immunogenicity, and the discordance between circulating 
influenza strains and those included in annual vaccine formulations3,5–7.
The adaptive immune system is conceptually divided into humoral and cell-mediated immunity (CMI). The 
humoral arm is responsible for production of neutralizing antibodies, support antibody-dependent cellular cyto-
toxicity, opsonization and complement fixation, whereas the cellular arm allows for direct killing of the patho-
gen and assists in the production of neutralizing antibodies8. Both arms are important in the immune response 
against natural influenza infection8, and it is unclear whether the development of cellular or humoral immunity is 
a better correlate of protection against subsequent infection. Most of the data available about the development of 
immunity against natural influenza infection are focused on the antibody responses. This is most likely related to 
the fact that measurement of humoral immunity is significantly less labour-intensive, there is standardization of 
assays and a better consensus on cut-off values required for protection. However, some studies in immunocom-
petent persons show that CMI may be a better correlate of protection against influenza than humoral immunity 
in vaccinated patients with poor immune responses9,10. Moreover, CMI seems to be important in recovery from 
influenza infection and in virus clearance, and possibly in preventing complications, rather than strictly prevent 
infection11. Organ transplant recipients are on T-cell suppressing therapies which may impact formation of CMI 
responses not only against vaccine but also against influenza infection. The aim of our study was therefore to 
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evaluate the CD4 + and CD8 + T-cell responses during natural influenza infection in a cohort of SOT patients 
and to compare it to the T-cell responses elicited by the influenza vaccine in this population.
Results
Influenza infection. Demographics. Thirty-five patients were enrolled between December 2017 and May 
2018. Four patients were subsequently excluded from analysis because of unavailable PBMCs either at diagnosis 
or at follow-up. Among the 31 patients who completed the study, median time between symptom onset and 
blood collection was 6 days (interquartile range [IQR] 4–11) and median time between diagnosis and blood 
collection was 3 days (IQR 2–4). Median time between acute and convalescent specimen collection was 38 days 
(IQR 29–50). One patient underwent re-transplantation between the two specimens collection. Patient demo-
graphics are detailed in Table 1. Fifteen patients were infected with Influenza A and 16 with influenza B (Table 2). 
All influenza-infected patients received a 5-day course of oseltamivir within a median of 6 days (IQR 4–11) after 
symptom onset (Table 2).
CD4+ and CD8+ T-cell immunity at influenza diagnosis. Among patients infected with influenza A/H3N2, the 
median number of influenza A/H3N2-specific cytokine-producing T-cells at baseline ranged between 1-248 and 
1–8 cells per 106 CD4+ and CD8+ T-cells, respectively (Fig. 1 and Supplementary Table T1 online). Patients 
infected with influenza A/H1N1 (n = 2) had influenza A/H1N1-specific cytokine producing T-cells ranging 
between 1–28 and 1–41 cells per 106 CD4+ and CD8+ T-cells, respectively (Supplementary Table T1 online). The 
median number of influenza B-specific cytokine producing T-cells at baseline ranged between 171–997 and 1-405 
cells per 106 CD4+ and CD8+ T-cells, respectively (Fig. 1 and Supplementary Table T1 online).
CD4+ and CD8+ T-cell immunity 28 days after influenza infection. Among patients infected with influ-
enza A/H3N2, the median number of influenza A/H3N2-specific cytokine-producing CD4+ T-cells 28 days 
post-diagnosis ranged between 534–1577 cells per 106 CD4+ T-cells. This represented a significant increase 
relative to the time of diagnosis for IL2+ (p = 0.006), TNFα+ (p = 0.004) and polyfunctional (p = 0.006) 
CD4+ T-cells (Fig. 1 and Supplementary Table T1 online). The median number of influenza A/H3N2-specific 
cytokine-producing CD8+ T-cells ranged between 1-1,312 cells per 106 CD8+ T-cells. There was no signifi-
cant increase in the number of influenza A/H3N2-specific cytokine-producing CD8+ T-cells at Day 28 when 
compared to baseline (Fig. 1 and Supplementary Table T1 online). Patients infected with influenza A/H1N1 
(n = 2) had influenza A/H1N1-specific cytokine producing T-cells ranging between 1–1,739 and 1-959 cells 
per 106 CD4+ and CD8+ T-cells, respectively (Supplementary Table T1 online). The median number of influ-
enza B-specific cytokine-producing CD4+ T-cells ranged between 1-1,957 cells per 106 CD4+ T-cells. This 
Influenza 
infection (n = 31)
Influenza 
vaccine (n = 25) p-value
Demographics
Age, y, median (IQR) 54.8 (39.0–63.9) 59.0 (49.5–62.5) 0.239
Male sex 19 (61.3) 22 (88.0) 0.034
Time after transplant, y, median 
(IQR) 2.4 (0.2–4.9) 3.5 (1.0–7.5) 0.259
Type of transplant
Kidney 13 (41.9) 6 (24.0)
0.001
Liver 0 (0) 5 (20.0)
Lung 16 (51.6) 5 (20.0)
Heart 2 (6.5) 4 (16.0)
Combined 0 (0) 5 (20.0)
Immunosuppression
ATG in the last 3 months 4 (12.9) 1 (4.0) 0.367
Prednisone 31 (100) 19 (76.0) 0.005
           daily dose (mg), median 
(IQR) 15.0 (7.5–20.0) 5.0 (1.3–5.0) <0.001
Calcineurin inhibitor 31 (100) 31 (100) —
Tacrolimus 16 (51.6) 16 (64.0) 0.352
          trough (µg/l), median (IQR) 8.1 (5.9–12.5) 6.8 (4.4–8.9) 0.251
Cyclosporine 15 (48.4) 9 (36.0) 0.352
          trough (µg/l), median (IQR) 206 (163–256) 145 (102–271) 0.283
Sirolimus 0 (0) 1 (4.0) 0.446
MMF 19 (61.3) 18 (72.0) 0.4
           daily dose (mg), median 
(IQR) 1440 (720–1440) 1040 (720–1440) 0.169
Azathioprine 1 (3.2) 3 (12.0) 0.314
Table 1. Demographics and Immunosuppression Regimens of Transplant Recipients in the Influenza Infection 
and Vaccine Cohorts. IQR: interquartile range; ATG: antithymocyte globulin; MMF: mycophenolate mofetil.
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represented a significant increase when compared to diagnosis for TNFα+ (p = 0.002) and polyfunctional 
(p = 0.004) CD4+ T-cells (Fig. 1 and Supplementary Table T1 online). The median number of influenza B-specific 
cytokine-producing CD8+ T-cells ranged between 1–28 cells per 106 CD8+ T-cells. There was no significant 
increase in the number of influenza B-specific cytokine-producing CD8+ T-cells at Day 28 when compared to the 
time of diagnosis (Fig. 1 and Supplementary Table T1 online).
Receipt of the TIV during the same influenza season did not impact the magnitude of the subsequent 
influenza-specific CD4+ T-cells response at influenza diagnosis or at Day 28 (Supplementary Fig. S1 online). 
Similarly, receipt of the TIV during the same influenza season did not impact the magnitude of the subsequent 
influenza-specific CD8+ T-cells response, with the exception of a stronger IL2+CD8+ T-cell response at influenza 
diagnosis among patients who received the TIV (p = 0.039; Supplementary Fig. S1 online).
The relative contribution of each cytokine to polyfunctional CD4+ and CD8+ T-cells in influenza A/H3N2- 
and B-infected patients is detailed in Supplementary Fig. S2 and S3 online. Interestingly, less than 20% of poly-
functional cells were triple-positive cells (Supplementary Fig. S2 and S3 online).
Analysis of heterosubtypic CD4+ and CD8+ T-cell immunity among influenza A-infected patients. Among influ-
enza A/H3N2-infected patients, stimulation with H1N1 elicited a significant increase in IL2+, TNFα+ and poly-
functional CD4+ T-cells (Fig. 2), as seen with stimulation with H3N2 (Fig. 1) suggesting that natural infection 
Patients (n = 31)
Infection
Influenza, n(%)
A/H1N1 2 (6.5)
A/H3N2 13 (41.9)
B 16 (51.6)
Symptoms, n(%)
Fever 19 (61.3)
Sore throat 15 (48.4)
Cough 30 (96.8)
Myalgia 12 (38.7)
Dyspnea 22 (71.0)
Headache 14 (45.2)
Rhinorrhea 19 (61.3)
Nausea or vomiting 8 (25.8)
Diarrhea 8 (25.8)
Fatigue 5 (16.1)
Management
Oseltamivir, n (%) 31 (100)
Median daily dose, mg (IQR) 75 (60–150)
Median duration, days (IQR) 5 (5–5)
Median time symptom onset and antivirals, 
days (IQR) 6 (4–11)
Complications
Admission, n (%) 28 (90.3)
Median duration admission, days (IQR) 5 (2–10)
Pneumonia, n (%) 12 (38.7)
Death at 6 months*, n (%) 3 (9.7)
Rejection in the month prior or the 3 months 
after infection#, n (%) 2 (6.5)
Influenza immunization, n (%)
Same season 18/27 (66.7)
Previous season 17/24 (70.8)
Laboratory results
Median creatinine clearance, mL/mn (IQR) 54 (33–81)
Median leukocyte count, G/l (IQR) 4.6 (4.0–6.3)
Median neutrophil count, G/l (IQR) 3.6 (1.5–5.4)
Median lymphocyte count, G/l (IQR) 0.7 (0.4–1.1)
Table 2. Characteristics of Transplant Recipients With Influenza Infection. *Causes of death were: bleeding 
from fistula 3 months following influenza infection (n = 1), M.abscessus infection 4 months after influenza 
infection (n = 1) and chronic lung allograft dysfunction 4 months after influenza infection (n = 1) #Grade 1–2 
rejection in the month preceeding influenza infection (n = 1), Grade 2 rejection 3 weeks following influenza 
infection (n = 1) IQR: interquartile range.
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does result in heterosubtypic immunity. Interestingly, in this group, stimulation with H1N1 also elicited a sig-
nificant increase in TNFα+ and polyfunctional CD8+ T-cells (Fig. 2), which was not seen with stimulation with 
H3N2 (Fig. 1).
Figure 1. Evaluation of influenza-specific CD4+ and CD8+ T-cell immunity among influenza A/H3N2- and 
influenza B-infected patients at influenza diagnosis and Day 28. IFN-γ: interferon-γ; TNF-α: tumor-necrosis 
factor-α; IL: interleukin. Results were expressed as number of cytokine-producing CD4+ cells/106 CD4+ T-cells 
or CD8+ cells/106 CD8+ T-cells. For data presentation, cell frequencies labelled as TNFα+, IFNγ+, IL2+ or 
IL4+ were cells producing the given cytokine, regardless of the production of other cytokines. The upper edge 
of the box represents the median value, and the error bars represent the interquartile range. Red and blue dots 
represent individual patient frequencies at influenza diagnosis and Day 28, respectively.
Figure 2. Evaluation of heterosubtypic influenza A/H1N1-specific CD4+ and CD8+ T-cell immunity among 
influenza A/H3N2-infected patients IFN-γ: interferon-γ; TNF-α: tumor-necrosis factor-α; IL: interleukin. 
Results were expressed as number of cytokine-producing CD4+ cells/106 CD4+ T-cells or CD8+ cells/106 CD8+ 
T-cells. For data presentation, cell frequencies labelled as TNFα+, IFNγ+, IL2+ or IL4+ were cells producing 
the given cytokine, regardless of the production of other cytokines. The upper edge of the box represents the 
median value, and the error bars represent the interquartile range. Black and green dots represent individual 
frequencies in influenza A/H3N2-infected patients at influenza diagnosis and Day 28, respectively.
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Among influenza A/H1N1-infected patients (n = 2), there was a CD4+ and CD8+ T-cell response to H3N2 
stimulation at a similar level compared the response to H1N1 stimulation (data not shown).
Outcomes measures associated with polyfunctional CD4+ and CD8+ T-cells. There was a trend towards an associ-
ation between protection from pneumonia or death and the presence of polyfunctional CD4+ T-cells at influenza 
diagnosis (83.3% [15/18] vs 53.8% [7/13]; p = 0.084). However, there was no association between protection from 
pneumonia or death and the presence of polyfunctional CD4+ T-cells at Day 28 (100% [18/18] vs 92.3% [12/13]; 
p = 0.419).
There was no association between protection against pneumonia or death and the presence of polyfunctional 
CD8+ T-cells, both at influenza diagnosis (38.9% [7/18] vs 38.5% [5/13]; p = 0.638) or at Day 28 (44.4% [8/18] vs 
38.5% [5/13]; p = 0.516).
Comparison of infection-elicited and vaccine-elicited responses. Demographics. We compared 
the T-cell responses elicited by influenza infection to the responses elicited by influenza vaccine in 25 SOT 
patients. There was no significant difference in age or time since SOT between the two groups (Table 1). There 
were significantly more lung transplant recipients in the influenza infection group. The influenza infection group 
was also more likely to be on prednisone and prednisone daily doses were higher (Table 1).
Cellular immunity. The proportion of infection-elicited IFNγ+, IL4+ and polyfunctional CD4+ T-cells among 
influenza A/H1N1-infected patients were significantly greater than vaccine-elicited CD4+ T-cells against influ-
enza A/H1N1 (p = 0.033, 0.026 and 0.042 respectively) (Fig. 3 and Supplementary Fig. S4 online). Similarly, the 
proportion of infection-elicited TNFα+, IL2+ and polyfunctional CD4+ T-cells was significantly higher among 
influenza A/H3N2-infected (p = 0.038, 0.017 and 0.041 respectively) and influenza B-infected patients (p = 0.002, 
0.048 and 0.004 respectively) than in vaccine recipients (Fig. 3 and Supplementary Fig. S4 online).
In general, the proportion of cytokine-producing CD8+ T-cells did not significantly differ between vacci-
nated and infected patients, with the exception of a higher frequency IL2+ CD8+ T-cells among influenza A/
H1N1-infected patients when compared to vaccinated patients e (p = 0.021) (Fig. 3 and Supplementary Fig. S5 
online).
Discussion
We evaluated the dynamics of influenza-specific cell-mediated immunity in a cohort of SOT patients infected 
with influenza and compared T-cell responses to a cohort of vaccinated patients. Our study shows that influenza 
infection elicited T-cell responses primarily for CD4+. These responses also appear to be cross-reactive with other 
influenza strains (heterosubtypic response). We also showed that T-cell responses were significantly greater in 
infected patients compared to vaccinated patients. This was true not only for monofunctional cells, but also for 
polyfunctional cells, which may be a better correlate of the quality of the immune response. Our study provides 
novel comparative data on cellular immune response to natural vs. vaccine responses in transplant patients.
Upon infection, influenza virus activates innate immune components, leading eventually to the generation of 
influenza-specific CD8+ and CD4+ T-cell responses, both of which are important in controlling influenza infection18. 
CD8+ T-cells differentiate into cytotoxic T lymphocytes which control viral replication and kill infected cells 
through production of cytokines and effector molecules12. On the other hand, CD4 + T-cells activate B-cells 
to produce antibodies, but also target infected-cells12. There are limited data in transplant recipients looking 
at short-term T-cell response to seasonal influenza infection. Our group previously looked at long-term T-cell 
responses to influenza A/H1N1pdm in a cohort of 22 transplant recipients that had been infected with influ-
enza during the 2009 influenza pandemic. At a median of 7 months post-infection, influenza-specific CD4 + and 
Figure 3. Comparison of median number of influenza-specific infection-elicited and vaccine-elicited cytokine-
producing CD4+ and CD8+ T-cells in SOT recipients. SOT: Solid organ transplant; IFN-γ: interferon-γ; 
TNF-α: tumor-necrosis factor-α; IL: interleukin. Results were expressed as number of vaccine-elicited 
cytokine-producing CD4+ cells/106 CD4+ T-cells and number of cytokine-producing CD8+ cells/106 CD8+ 
T-cells. For data presentation, cell frequencies labelled as TNFα+, IFNγ+, IL2+ or IL4+ were cells producing 
the given cytokine, regardless of the production of other cytokines. The boxes represents the median value. 
Pre-vaccination frequencies were subtracted from post-vaccination frequencies to highlight vaccine-elicited 
responses, whereas frequencies at influenza diagnosis were subtracted from frequencies at Day 28 to highlight 
infection-elicited responses.
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CD8 + T-cells responses were found in 50% and 36%, respectively13. This is consistent with the current study 
which also shows a predominantly CD4 + T-cell response. We also showed that both influenza A and B infections 
elicited a significant increase in polyfunctional CD4 + T-cells, which are considered to be a good correlate of the 
quality of the T-cell response14.
Several studies have demonstrated the importance of polyfunctional CD4 + T-cells in the control of influ-
enza in non-transplant patients. Polyfunctional influenza-specific CD4+ cells have been shown to be functionally 
superior, as shown by increased degranulation and higher production of CD40L and cytokine per cell15. In a 
cohort of pregnant women infected with influenza A/H1N1pdm, the proportion of polyfunctional CD4 + T-cells 
was inversely correlated with influenza disease severity16, confirming murine data where polyfunctional cells 
also protected against lethal influenza infection17. Similarly, polyfunctional cells have been associated with better 
protection after vaccination and better outcomes in several other models18,19. In our cohort, there was a trend 
towards an association between the presence of polyfunctional CD4 + T-cells at influenza diagnosis and reduced 
disease severity. The development of CMI is especially important in older adults age ≥65 years who are known to 
derive poor protection from vaccination. In this group, CMI may be a better correlate of protection than antibody 
response9,10. We postulate that CMI likely has a major role to play in SOT patients as well.
In our current infected cohort, 67% had received the influenza vaccine prior to being infected. Interestingly, 
there was no difference in the T-cell responses at influenza diagnosis or at Day 28 in vaccinated vs. unvaccinated 
patients. This may be due to the size of the cohort or the lack of sustained T-cell responses following the vaccine.
We also showed evidence that transplant patients can develop heterosubtypic immunity as evidenced by 
response to H1N1 stimulation in H3N2-infected patients. The heterosubtypic response may be mediated by T-cell 
immunity directed against conserved influenza antigens20. We did not find that infection elicited a significant 
homotypic or heterosubtypic CD8+ T-cell response. CD8+ T-cell responses are important in cytotoxicity and are 
the basis of some CD8+ directed universal influenza vaccines. There are several possible explanations for the low 
CD8+ responses observed in our study. First, the antigen used for stimulation was calibrated on HA concentra-
tion, which is known to predominantly stimulate CD4+ responses whereas internal influenza proteins such as 
M1 and NP predominantly stimulate CD8+ responses21. The use of inactivated virus calibrated on HA concen-
tration could potentially have underestimated CD8+ responses, even though it is not possible to know whether 
the other antigens – including internal proteins - were in lower, similar or higher respective concentration than 
HA. Another reason for lower CD8+ responses may be that we did not use a more sensitive technique such as 
EliSPOT or Fluorospot. Finally, the low CD8+ responses might be related to the iatrogenic immunosuppression 
in our cohort that could affect CD8+ responses to a greater extent than CD4 + responses; this is supported by data 
showing stronger CD4+ than CD8+ responses against pandemic H1N1 in SOT patients while using live virus for 
stimulation13. Therefore, even if SOT patients may mount significant CD8+ responses, we did not demonstrate 
these in the current study. It is interesting that we have previously found polyfunctional CD8+ T-cell responses in 
SOT patients who were vaccinated with high-dose TIV22 but less so with natural infection. There may be a num-
ber of reasons for this. Unlike vaccination, infection may generate CD8 + immune-escaped variants in immuno-
compromised patients23. Vaccination also occurs intramuscularly and in high antigenic doses which may skew 
responses. On the other hand, infection is mucosal and the immune response may be directed against different 
epitopes. Therefore, the antigens used to re-stimulate the response in an experimental setting may not be the same 
as the response against the circulating strain.
One of the main findings of our study is that CD4+ responses in infected patients were significantly greater 
than those in noninfected, vaccinated patients. This finding occurred despite some important differences between 
the two cohorts that would suggest the infected cohort might have had poorer immune responses. The infected 
cohort had significantly more lung transplant recipients and more patients receiving prednisone along with 
higher daily doses of prednisone. Despite the potential for greater immunosuppression in the infected group, 
T-cell responses were greater. In general, natural infection should elicit a greater T-cell response than vaccina-
tion. For example, in healthy adults, the influenza vaccine is associated with lower antibody titers and rapidly 
waning antibodies when compared to natural influenza infection24,25. Prior data in the general population has 
shown that CMI responses to influenza vaccine are diminished compared to CMI generated with natural infec-
tion26,27. Interestingly, in our study, the influenza vaccine elicited a predominant IL2 + CD4 + response to H1N1 
whereas influenza infection elicited a predominant IFNγ + CD4 + response, which is in line with previous data28. 
Interestingly, the high-dose split-virus influenza vaccine (FluzoneHD, Sanofi, Canada) elicited CD4+ and CD8+ 
T-cell responses at a similar level compared to influenza infection, using the same flow cytometry parameters22.
This study has some limitations. Our sample size was relatively small, even though we were still able to show a 
significant increase in CMI after infection and significant differences in CMI when compared to patients from the 
vaccine study. The sample size however did not allow to define correlates of protection against severe outcomes. 
There were only two A/H1N1-infected patients in our cohort likely because the local predominant circulating 
strains were A/H3N2 and B in respectively 46% and 50% of cases during the 2017–2018 season29. Serum was 
not collected, which did not allow to evaluate whether there was a correlation between humoral and cellular 
responses. We also did not examine heterosubtypic responses to other influenza B strains. Influenza infected 
patients were enrolled in a different season than vaccinated patients and this may have introduced variabil-
ity into the results. However, our cell stimulations were based on antigens corresponding to circulating wild 
strains and strains included in the vaccine formulation. There was an enrollment bias towards admitted patients. 
Moreover, median time between symptom onset and blood collection was six days, which could have biased our 
interpretation of T-cell responses at influenza diagnosis infection onset because of an already ongoing immune 
response. However, the bias would underestimate the infection-elicited responses as well as differences between 
infection-elicited and vaccine-elicited responses, which would further strengthen our findings. Our study did not 
define which influenza proteins/epitopes were responsible for the effector responses and this could be done in 
future studies. Similarly, the fact that we used inactivated viruses quantified on HA concentration and not internal 
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proteins might have biased the responses towards CD4 and therefore does not allow strong conclusions about 
CD8 + responses. Finally, although this was not the primary goal of our study, comparing our data with a control 
group of healthy adults infected with influenza would also allow further insights.
In conclusion, our study provides novel data on the cellular immune response to influenza in SOT patients, 
and shows that natural influenza infection elicited a significant increase in monofunctional and polyfunctional 
influenza-specific CD4+ T-cells. Interestingly, among patients infected with influenza A, heterosubtypic and 
homotypic stimulation elicited a similar T-cell response, suggesting potential cross-protective immunity. Finally, 
the level of the T-cell response following natural influenza infection was significantly higher than the response 
following the TIV. More studies are required to evaluate how this translates in term of protection against (re)
infection.
Methods
Study design. Adult organ transplant recipients at the Toronto Transplant Program were enrolled if they had 
microbiologically confirmed influenza infection during the 2017–2018 influenza season. Whole blood for periph-
eral blood mononuclear cells (PBMC) isolation was collected at diagnosis and 4 weeks post-diagnosis. The study 
was approved by the University Health Network research ethics board and written consent was obtained from 
all patients before data and specimen collection. Detailed clinical information was gathered and patients were 
followed for six months following influenza diagnosis. Vaccinated patients were also adult organ transplant recip-
ients and were enrolled as part of a randomized trial of influenza vaccination conducted during the 2016–2017 
influenza season30. For purposes of the current study, only patients that received standard split-virus trivalent 
influenza vaccine (TIV) (Fluviral, GSK, Canada) and provided PBMCs in that trial were used as a comparison 
group. All methods were performed in accordance with the relevant guidelines and regulations, including the 
Declaration of Helsinki. No organ or tissue was procured from prisoners.
Influenza diagnosis and subtyping. Influenza was diagnosed using the Luminex Aries Flu A/B & RSV 
PCR assay (Luminex Corporation, Austin, TX, USA) on nasopharyngeal (NP) swab or broncho-alveolar lavage 
(BAL) specimens. Influenza A was subtyped at the Public Health Ontario Laboratories (PHOL) using an in-house 
real-time PCR for which primer and probe sequences were based on Centers for Disease Control (CDC) refer-
ences and target HA surface protein31.
PBMC Stimulation and Flow Cytometry. For influenza infected patients, whole blood was obtained 
at influenza diagnosis and 28 days later. PBMCs were immediately isolated from blood using Ficoll (GE 
Healthcare Life Science, Issaquah, WA, USA) gradient centrifugation and cryopreserved in fetal bovine serum 
(ThermoFisher Scientific, Waltham, MA, USA) with 10% dimethyl sulfoxide (Fisher BioReagents, ThermoFisher 
Scientific), as previously described22. To determine influenza-specific T-cell responses 5×105 PBMCs were stim-
ulated immediately after thawing with 1 µg/ml of either influenza antigens corresponding to circulating seasonal 
H1N1, H3N2 or B viruses or media alone for 16 hours. The anti-human CD28/CD49d co-stimulatory reagent 
(BD FastImmuneTM, BD Biosciences, Mississauga, ON, Canada) and protein transport inhibitor (eBioscience, 
ThermoFisher Scientific) were also added immediately after thawing, as previously described22. Viral antigens 
corresponding to A/Michigan/45/2015 (H1N1), A/Hong Kong/4801/2014 (H3N2) and B/Phuket/3073/2013 were 
obtained from the National Institute for Biological Standards and Control (NIBSC, Hertfordshire, UK) and recon-
stituted according to the manufacturer’s instructions (Influenza Antigens A/Michigan/45/2015 [NYMC X-275; 
NIBSC code 17/154], A/Hong Kong/4801/2014 [NYMCX-263B; NIBSC code 16/286] and B/Phuket/3073/2013 
[NIBSC code 16/168], respectively). These antigens corresponded to respectively 100%, 100% and 98.6% of 
H1N1, H3N2 and B strains typed in Ontario, Canada during the 2017–2018 influenza season in which patients 
were enrolled29. For influenza B-infected patients, only homotypic responses were evaluated whereas homotypic 
and heterosubtypic responses were evaluated for influenza A-infected patients. Heterosubtypic responses were 
defined as a T-cell response to a different influenza subtype than the subtype which infected the patient (eg, T-cell 
response to influenza A/H1N1 for patients infected with A/H3N2).
For patients who received the vaccine, PBMCs were obtained pre-vaccination and 4 weeks post-vaccination 
and were stimulated with the viral antigens that corresponded to the antigens in the 2016–2017 trivalent vaccine 
and obtained from the NIBSC, as previously described22.
Following stimulation, cells were spun down and stained with the Zombie NIRTM viability dye (BioLegend, 
San Diego, CA, USA). Following Fc receptor blocking using Human BD Fc Block (BD Biosciences), cells were 
incubated with a cell-surface cocktail consisting of [mouse] anti-human CD45 (clone HI30)-PerCP/Cy5.5 
(Biolegend), [mouse] anti-human CD3 (clone OKT3)-PE/Cy7 (Biolegend), [mouse] anti-human CD4 (clone 
SK3)-Pacific Blue (Biolegend), [mouse] and anti-human CD8 (clone RPA-T8)-V500 (BD Biosciences), as pre-
viously described22. Following incubation with fixation buffer (BioLegend) cells were treated with an intracel-
lular cytokine antibody cocktail prepared in Intracellular Staining Permeabilization Wash Buffer (BioLegend)22. 
The intracellular cocktail consisted of [mouse] anti-human interferon (IFN)-γ (clone 4 S.B3)-FITC (Biolegend), 
[mouse] anti-human tumor-necrosis factor (TNF)-α (clone MAb11)-BV605 (Biolegend), [rat] anti-human inter-
leukin (IL)-2 (clone MQ1–17H12)-BV650 (Biolegend), and [rat] anti-human IL-4 (clone MP4–25D2)-PE-Dazzle 
(Biolegend), as previously described22. Flow cytometry was performed on a BD LSR II at The SickKids-UHN 
Flow and Mass Cytometry Facility (Toronto, ON, Canada) with a target event count of 100,000 live, CD45+ 
cells. The data acquired was analysed using FlowJo software v10 (FlowJo LLC, Ashland, OR, USA). To account 
for background cytokine production, the frequency of cytokine-production obtained in the unstimulated 
specimen was subtracted from the frequency obtained in the stimulated specimen. Furthermore, to compare 
infection-elicited and vaccine-elicited responses, the frequencies of cytokine-producing cells at influenza diag-
nosis were subtracted from the frequencies at Day 28, whereas pre-vaccination frequencies were subtracted from 
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the frequency post-vaccination. In the absence of vaccine-associated response, specimens were given a value 
of 1 cytokine-producing cell per 106 CD4+ or CD8+ T-cells. For data presentation, cell frequencies labelled as 
TNFα+, IFNγ+, IL2+ or IL4+ were cells producing the given cytokine, regardless of the production of other 
cytokines. Polyfunctional cells were defined as cells producing two or more cytokines out of IFN-γ, TNF-α and 
IL-2 as determined using Boolean gating. We did not consider IL-4 as part of polyfunctionality based on previous 
published data that focuses primarily on TNF-α, IFN-γ, and IL-2, which are a typical Th1 subset18,19. However, 
given the importance of IL-4 as a hallmark Th2 cytokine, IL-4 was evaluated as an individual cytokine along with 
TNF-α, IFN-γ, and IL-2. A representative gating strategy for the identification of cytokine-producing CD4+ 
and CD8+ T-cells is presented in Supplementary Fig. S6 online. Cell counts of cytokine-producing cells were 
expressed per 106 CD4+ or CD8+ T-cells.
Statistical analysis. Analyses were performed in infected patients only for which specimens were available 
both at influenza diagnosis and at Day 28 (per-protocol analysis). For group comparisons, Chi-squared or Fisher 
exact test were used for categorical variables, whereas Mann-Whitney U test was used for continuous unrelated 
variables and Wilcoxon signed rank test was used for continuous, paired variables. A composite outcome of 
pneumonia and death was chosen as a marker of disease severity and used to evaluate whether the presence of 
polyfunctional cells (defined here as polyfunctional cells in frequencies greater than 0% of the parent gate once 
normalised to the background control) protected against adverse outcomes. Statistics were performed using SPSS 
version 23.0 (IBM Corp., Armonk, NY, USA). Figures were made using GraphPad 7.0 (LaJolla, CA, USA).
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